资讯

BioSpace

ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First ...

Ninth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s ENHERTU with the latest based on DESTINY-Breast09 phase 3 trial results Thirteenth Breakthrough Therapy Designation granted ...
Associated Press

US economy shrank 0.5% in the first quarter, worse than earlier estimates had revealed

Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. A shopper pushes a cart past a display of soups in ...
Fox Business

US economy shrank 0.5% in the first quarter of 2025 amid tariff uncertainty

The U.S. economy contracted in the first quarter as tariffs caused importers to surge shipments before higher levies took effect. The Commerce Department's Bureau of Economic Analysis (BEA) released ...
Frontiers

Rituximab as the first-line treatment in newly diagnosed systemic lupus erythematosus

Objectives: Rituximab (RTX) has been commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE), yet real-world data concerning RTX as the first-line ...
Morningstar

Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer ...

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a ...
BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination with ...